Research programme: paediatric film formulations - Lupin Pharmaceuticals

Drug Profile

Research programme: paediatric film formulations - Lupin Pharmaceuticals

Latest Information Update: 08 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lupin Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Attention-deficit hyperactivity disorder

Most Recent Events

  • 06 Oct 2016 Lupin Pharmaceuticals in-licenses PharmFilm® technology from MonoSol Rx
  • 06 Oct 2016 Early research in Attention-deficit hyperactivity disorder in USA (PO) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top